| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Research and development | 12,034 | 12,340 | 12,042 | 13,340 |
| General and administrative | 7,337 | 7,195 | 7,223 | 6,448 |
| Total operating expenses | 19,371 | 19,535 | 19,265 | 19,788 |
| Loss from operations | -19,371 | -19,535 | -19,265 | -19,788 |
| Other income, net | 1,791 | 1,892 | 2,100 | 1,356 |
| Net loss | -17,580 | -17,643 | -17,165 | -18,432 |
| Unrealized gain on marketable securities | 84 | -19 | -15 | 154 |
| Total comprehensive loss | -17,496 | -17,662 | -17,180 | -18,278 |
| Net loss per share, basic | -0.65 | -0.65 | -0.08 | -0.47 |
| Net loss per share, diluted | -0.65 | -0.65 | -0.08 | -0.47 |
| Weighted-average shares used to compute net loss per share, basic | 26,963,107 | 26,949,752 | 215,410,253 | 38,903,476 |
| Weighted-average shares used to compute net loss per share, diluted | 26,963,107 | 26,949,752 | 215,410,253 | 38,903,476 |
RAPT Therapeutics, Inc. (RAPT)
RAPT Therapeutics, Inc. (RAPT)